TerraForm Global Announces Extension Until June 30, 2017 to Regain Nasdaq Compliance

Mar 21, 2017 13:03 pm UTC| Business

BETHESDA, Md., March 21, 2017 -- TerraForm Global, Inc. (Nasdaq:GLBL) (“TerraForm Global” or the “Company”), a global owner and operator of clean energy power plants, announced today that the Nasdaq Hearings Panel...

TerraForm Global Announces Extension Until June 30, 2017 to Regain Nasdaq Compliance

Mar 21, 2017 13:03 pm UTC| Business

BETHESDA, Md., March 21, 2017 -- TerraForm Global, Inc. (Nasdaq:GLBL) (“TerraForm Global” or the “Company”), a global owner and operator of clean energy power plants, announced today that the Nasdaq Hearings Panel...

RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease

Mar 21, 2017 13:03 pm UTC| Business

A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional countriesThe open-label extension...

RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease

Mar 21, 2017 13:03 pm UTC| Business

A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional countriesThe open-label extension...

RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease

Mar 21, 2017 13:03 pm UTC| Business

A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional countriesThe open-label extension...

RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease

Mar 21, 2017 13:03 pm UTC| Business

A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional countriesThe open-label extension...

Finisar Demonstrates New 400G, 200G and 100G Pluggable Optical Modules and Introduces Flexgrid® Single Low Profile Wavelength Selective Switch at OFC 2017

Mar 21, 2017 13:02 pm UTC| Business

SUNNYVALE, Calif., March 21, 2017 -- Finisar (NASDAQ:FNSR) today announced multiple optics product and technology demonstrations to be held this week during the OFC exhibition. The company will feature new module types,...